1. Fresenius is showing significant upside with a 25% RoR since early 2024; 2. The turnaround is evident with improved EPS, reduced leverage, and strong performance in key segments like Kabi and Helios; 3. A conservative price target of €35/share is expected to yield a 60% RoR in the next 3 years.